Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Save your unit preferences in settings!

    Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    Measures treatment response, specifically to cytotoxic drugs, based on tumor shrinkage.
    Favorite

    INSTRUCTIONS

    Use in liver lesions meeting the following criteria:

    • Can be accurately measured in at least one dimension as 10 mm or more (measure longest diameter).
    • Suitable for repeat measurement.
    • Intratumoral arterial enhancement on contrast-enhanced CT or MRI.
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with hepatocellular carcinoma (HCC) who have undergone treatment (systemic, locoregional, and/or surgical).

    • Can identify patients who are not responding to therapy, in order to help guide decisions about modification of therapy, more quickly than traditional endpoints like morbidity and mortality.
    • Tumor response, while an important surrogate for efficacy of cancer treatment, is not equivalent to overall survival.
    • Specific to HCC, unlike the original RECIST.
    • Based on expert consensus and not yet validated against gold standard (pathologic examination of explanted livers), though widely used.
    • HCC patients undergo complex multimodal therapies, including systemic cytotoxic chemotherapy, targeted therapy like sorafenib, locoregional treatment like transarterial chemoembolization (TACE) and radioembolization with Y90), and surgical resection. Imaging criteria (versus traditional endpoints of morbidity and mortality) can more quickly identify patients who are not responding to therapy to help guide decisions about modification of therapy.
    • Offers improved accuracy over previous criteria for tumor response (WHO and RECIST), which were developed based on data from patients receiving cytotoxic chemotherapy only.
    • Accounts for tumor necrosis induced by treatment (which can be misinterpreted as living tumor by WHO classification).
    mm
    mm

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    • Contrast-enhanced CT or MRI is the imaging modality of choice for evaluating lesions.
    • European Association for the Study of the Liver (EASL) guidelines recommend evaluating for mRECIST criteria 1 month after undergoing treatment (surgery, locoregional therapy or initiation of systemic chemotherapy).

    Management

    recist treatment hcc
     
    CR, complete response. PR, partial response. SD, stable disease. PD, progressive disease. IR, incomplete response.
    About the Creator
    Dr. Josep Llovet
    Are you Dr. Josep Llovet?